カテゴリ： 世界, 医療/バイオ, Market Monitor Global

DTaP＆Tdapワクチンのグローバル市場展望 2023年-2029年：DTaP、Td、Tdap

■ 英語タイトル：DTaP and Tdap Vaccines Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8501）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8501
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：77
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[DTaP＆Tdapワクチンのグローバル市場展望 2023年-2029年：DTaP、Td、Tdap]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のDTaP＆Tdapワクチン市場規模と予測を収録しています。・世界のDTaP＆Tdapワクチン市場：売上、2018年-2023年、2024年-2029年
・世界のDTaP＆Tdapワクチン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のDTaP＆Tdapワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「DTaP」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

DTaP＆Tdapワクチンのグローバル主要企業は、Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Incなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、DTaP＆Tdapワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のDTaP＆Tdapワクチン市場：タイプ別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：タイプ別市場シェア、2022年
・DTaP、Td、Tdap

世界のDTaP＆Tdapワクチン市場：用途別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：用途別市場シェア、2022年
・成人、小児

世界のDTaP＆Tdapワクチン市場：地域・国別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるDTaP＆Tdapワクチンのグローバル売上、2018年-2023年
・主要企業におけるDTaP＆Tdapワクチンのグローバル売上シェア、2022年
・主要企業におけるDTaP＆Tdapワクチンのグローバル販売量、2018年-2023年
・主要企業におけるDTaP＆Tdapワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Inc

*************************************************************

・調査・分析レポートの概要
DTaP＆Tdapワクチン市場の定義
市場セグメント
世界のDTaP＆Tdapワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のDTaP＆Tdapワクチン市場規模
世界のDTaP＆Tdapワクチン市場規模：2022年 VS 2029年
世界のDTaP＆Tdapワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのDTaP＆Tdapワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のDTaP＆Tdapワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：DTaP、Td、Tdap
DTaP＆Tdapワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：成人、小児
DTaP＆Tdapワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別DTaP＆Tdapワクチン市場規模 2022年と2029年
地域別DTaP＆Tdapワクチン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Inc
...

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
This report aims to provide a comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DTaP and Tdap Vaccines. This report contains market size and forecasts of DTaP and Tdap Vaccines in global, including the following market information:
Global DTaP and Tdap Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global DTaP and Tdap Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five DTaP and Tdap Vaccines companies in 2022 (%)
The global DTaP and Tdap Vaccines market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
DTaP Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of DTaP and Tdap Vaccines include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc and Johnson & Johnson, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the DTaP and Tdap Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global DTaP and Tdap Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, by Type, 2022 (%)
DTaP
Td
Tdap
Global DTaP and Tdap Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, by Application, 2022 (%)
Adult
Pediatric
Global DTaP and Tdap Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies DTaP and Tdap Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies DTaP and Tdap Vaccines revenues share in global market, 2022 (%)
Key companies DTaP and Tdap Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies DTaP and Tdap Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of DTaP and Tdap Vaccines, market overview.
Chapter 2: Global DTaP and Tdap Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of DTaP and Tdap Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global DTaP and Tdap Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 DTaP and Tdap Vaccines Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global DTaP and Tdap Vaccines Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global DTaP and Tdap Vaccines Overall Market Size
2.1 Global DTaP and Tdap Vaccines Market Size: 2022 VS 2029
2.2 Global DTaP and Tdap Vaccines Revenue, Prospects & Forecasts: 2018-2029
2.3 Global DTaP and Tdap Vaccines Sales: 2018-2029
3 Company Landscape
3.1 Top DTaP and Tdap Vaccines Players in Global Market
3.2 Top Global DTaP and Tdap Vaccines Companies Ranked by Revenue
3.3 Global DTaP and Tdap Vaccines Revenue by Companies
3.4 Global DTaP and Tdap Vaccines Sales by Companies
3.5 Global DTaP and Tdap Vaccines Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 DTaP and Tdap Vaccines Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers DTaP and Tdap Vaccines Product Type
3.8 Tier 1, Tier 2 and Tier 3 DTaP and Tdap Vaccines Players in Global Market
3.8.1 List of Global Tier 1 DTaP and Tdap Vaccines Companies
3.8.2 List of Global Tier 2 and Tier 3 DTaP and Tdap Vaccines Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global DTaP and Tdap Vaccines Market Size Markets, 2022 & 2029
4.1.2 DTaP
4.1.3 Td
4.1.4 Tdap
4.2 By Type – Global DTaP and Tdap Vaccines Revenue & Forecasts
4.2.1 By Type – Global DTaP and Tdap Vaccines Revenue, 2018-2023
4.2.2 By Type – Global DTaP and Tdap Vaccines Revenue, 2024-2029
4.2.3 By Type – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
4.3 By Type – Global DTaP and Tdap Vaccines Sales & Forecasts
4.3.1 By Type – Global DTaP and Tdap Vaccines Sales, 2018-2023
4.3.2 By Type – Global DTaP and Tdap Vaccines Sales, 2024-2029
4.3.3 By Type – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
4.4 By Type – Global DTaP and Tdap Vaccines Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global DTaP and Tdap Vaccines Market Size, 2022 & 2029
5.1.2 Adult
5.1.3 Pediatric
5.2 By Application – Global DTaP and Tdap Vaccines Revenue & Forecasts
5.2.1 By Application – Global DTaP and Tdap Vaccines Revenue, 2018-2023
5.2.2 By Application – Global DTaP and Tdap Vaccines Revenue, 2024-2029
5.2.3 By Application – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
5.3 By Application – Global DTaP and Tdap Vaccines Sales & Forecasts
5.3.1 By Application – Global DTaP and Tdap Vaccines Sales, 2018-2023
5.3.2 By Application – Global DTaP and Tdap Vaccines Sales, 2024-2029
5.3.3 By Application – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
5.4 By Application – Global DTaP and Tdap Vaccines Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global DTaP and Tdap Vaccines Market Size, 2022 & 2029
6.2 By Region – Global DTaP and Tdap Vaccines Revenue & Forecasts
6.2.1 By Region – Global DTaP and Tdap Vaccines Revenue, 2018-2023
6.2.2 By Region – Global DTaP and Tdap Vaccines Revenue, 2024-2029
6.2.3 By Region – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
6.3 By Region – Global DTaP and Tdap Vaccines Sales & Forecasts
6.3.1 By Region – Global DTaP and Tdap Vaccines Sales, 2018-2023
6.3.2 By Region – Global DTaP and Tdap Vaccines Sales, 2024-2029
6.3.3 By Region – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America DTaP and Tdap Vaccines Revenue, 2018-2029
6.4.2 By Country – North America DTaP and Tdap Vaccines Sales, 2018-2029
6.4.3 US DTaP and Tdap Vaccines Market Size, 2018-2029
6.4.4 Canada DTaP and Tdap Vaccines Market Size, 2018-2029
6.4.5 Mexico DTaP and Tdap Vaccines Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe DTaP and Tdap Vaccines Revenue, 2018-2029
6.5.2 By Country – Europe DTaP and Tdap Vaccines Sales, 2018-2029
6.5.3 Germany DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.4 France DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.5 U.K. DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.6 Italy DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.7 Russia DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.8 Nordic Countries DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.9 Benelux DTaP and Tdap Vaccines Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia DTaP and Tdap Vaccines Revenue, 2018-2029
6.6.2 By Region – Asia DTaP and Tdap Vaccines Sales, 2018-2029
6.6.3 China DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.4 Japan DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.5 South Korea DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.6 Southeast Asia DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.7 India DTaP and Tdap Vaccines Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America DTaP and Tdap Vaccines Revenue, 2018-2029
6.7.2 By Country – South America DTaP and Tdap Vaccines Sales, 2018-2029
6.7.3 Brazil DTaP and Tdap Vaccines Market Size, 2018-2029
6.7.4 Argentina DTaP and Tdap Vaccines Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa DTaP and Tdap Vaccines Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa DTaP and Tdap Vaccines Sales, 2018-2029
6.8.3 Turkey DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.4 Israel DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.5 Saudi Arabia DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.6 UAE DTaP and Tdap Vaccines Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi Pasteur
7.1.1 Sanofi Pasteur Company Summary
7.1.2 Sanofi Pasteur Business Overview
7.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Major Product Offerings
7.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Pasteur Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Major Product Offerings
7.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Protein Sciences Corporation
7.3.1 Protein Sciences Corporation Company Summary
7.3.2 Protein Sciences Corporation Business Overview
7.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Major Product Offerings
7.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.3.5 Protein Sciences Corporation Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG DTaP and Tdap Vaccines Major Product Offerings
7.4.4 Novartis AG DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Seqirus
7.5.1 Seqirus Company Summary
7.5.2 Seqirus Business Overview
7.5.3 Seqirus DTaP and Tdap Vaccines Major Product Offerings
7.5.4 Seqirus DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.5.5 Seqirus Key News & Latest Developments
7.6 Merck Sharp & Dohme Corp
7.6.1 Merck Sharp & Dohme Corp Company Summary
7.6.2 Merck Sharp & Dohme Corp Business Overview
7.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Major Product Offerings
7.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.6.5 Merck Sharp & Dohme Corp Key News & Latest Developments
7.7 Astellas Pharma US, Inc
7.7.1 Astellas Pharma US, Inc Company Summary
7.7.2 Astellas Pharma US, Inc Business Overview
7.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Major Product Offerings
7.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.7.5 Astellas Pharma US, Inc Key News & Latest Developments
7.8 Pfizer Inc
7.8.1 Pfizer Inc Company Summary
7.8.2 Pfizer Inc Business Overview
7.8.3 Pfizer Inc DTaP and Tdap Vaccines Major Product Offerings
7.8.4 Pfizer Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Inc Key News & Latest Developments
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Company Summary
7.9.2 Johnson & Johnson Business Overview
7.9.3 Johnson & Johnson DTaP and Tdap Vaccines Major Product Offerings
7.9.4 Johnson & Johnson DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.9.5 Johnson & Johnson Key News & Latest Developments
7.10 Lanzhou Institute of Biological Products Co., Ltd
7.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Summary
7.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
7.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Major Product Offerings
7.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.10.5 Lanzhou Institute of Biological Products Co., Ltd Key News & Latest Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Company Summary
7.11.2 AstraZeneca DTaP and Tdap Vaccines Business Overview
7.11.3 AstraZeneca DTaP and Tdap Vaccines Major Product Offerings
7.11.4 AstraZeneca DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.11.5 AstraZeneca Key News & Latest Developments
7.12 Emergent BioSolutions Inc
7.12.1 Emergent BioSolutions Inc Company Summary
7.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Business Overview
7.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Major Product Offerings
7.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.12.5 Emergent BioSolutions Inc Key News & Latest Developments
8 Global DTaP and Tdap Vaccines Production Capacity, Analysis
8.1 Global DTaP and Tdap Vaccines Production Capacity, 2018-2029
8.2 DTaP and Tdap Vaccines Production Capacity of Key Manufacturers in Global Market
8.3 Global DTaP and Tdap Vaccines Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 DTaP and Tdap Vaccines Supply Chain Analysis
10.1 DTaP and Tdap Vaccines Industry Value Chain
10.2 DTaP and Tdap Vaccines Upstream Market
10.3 DTaP and Tdap Vaccines Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 DTaP and Tdap Vaccines Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 破傷風ワクチンのグローバル市場展望 2023年-2029年：ジフテリア・破傷風（DT）ワクチン、ジフテリア・破傷風・百日咳（百日咳）（DTaP）ワクチン、破傷風・ジフテリア（Td）ワクチン、破傷風・ジフテリア・百日咳（Tdap）ワクチン
  • ポリオワクチンのグローバル市場展望 2023年-2029年：IPV、OPV
  • 卵ベースインフルエンザワクチンのグローバル市場展望 2023年-2029年：3価インフルエンザワクチン、4価インフルエンザワクチン
  • ハラール栄養補助食品＆ワクチンのグローバル市場展望 2023年-2029年：ハラールサプリメント、ハラールワクチン
  • 猫用ワクチンのグローバル市場展望 2023年-2029年：F3（FVRCP）ワクチン、猫白血病ワクチン、狂犬病予防接種、フィラリア予防接種、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8501 )"DTaP＆Tdapワクチンのグローバル市場展望 2023年-2029年：DTaP、Td、Tdap" (英文：DTaP and Tdap Vaccines Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。